Background and Aims: Conventional thiopurine [azathioprine and mercaptopurine] treatment during pregnancy in patients with inflammatory bowel disease [IBD] is considered to be safe; however data on the safety and teratogenicity of the non-conventional thiopurine tioguanine [TG] in pregnant IBD patients are lacking. We aim to describe the safety and teratogenicity of TG treatment during pregnancy in IBD patients. Methods: This was a retrospective, multicentre descriptive case series of female IBD patients using TG during pregnancy. Data on disease and medication history, pregnancy complications, pregnancy outcome, mode of delivery, preterm birth, birthweight, congenital abnormalities, laboratory signs of myelosuppression or hepatotoxicity, and 6-thioguaninenucleotide [6-TGN] concentrations in mother and neonate were collected. Results: In all, 13 patients [77% Crohn's disease, 23% ulcerative colitis] used TG [median dose 18 g/day] during pregnancy; 19 pregnancies, including 1 twin pregnancy, were included. Spontaneous abortion occurred in three pregnancies. In 7 of the 16 ongoing pregnancies a caesarean section was performed. One neonate had a mild congenital abnormality [distal shaft hypospadias]. In the singleton pregnancies, the median birthweight was 3410 g at a median of gestational age of 39 weeks. No preterm birth [< 37 weeks] or low birthweight [< 2500 g] was observed in the singleton newborns. In the twin pregnancy an induction of labour was performed at 35 + 1 weeks of gestation because of pre-eclampsia. Both neonates had a low birthweight.
Introduction
Inflammatory bowel disease [IBD] has a peak prevalence during the reproductive years. An exacerbation in disease activity during conception and pregnancy is associated with low birthweight and premature birth. 1, 2, 3 Consequently, it is of great importance that the safety profile of maintenance medication prescribed during pregnancy is balanced against the potential risk of disease relapse for both mother and fetus.
Conventional immune-modulating thiopurines, azathioprine [AZA] and mercaptopurine [MP] , have proven to be effective in IBD in both inducing and maintaining clinical remission. 4, 5 The use of these thiopurines during pregnancy is considered relatively safe. 6, 7, 8, 9, 10 In contrast to MP and its precursor AZA, the metabolism of tioguanine [TG] is relatively simple, as TG is more directly converted to the pharmacologically active 6-thioguaninenucleotides . Tioguanine [TG] is considered a potential rescue thiopurine which has shown to be effective in case of intolerance or resistance to conventional thiopurines. 11, 12, 13, 14 An unfavourable 'skewed' thiopurine metabolism, in which predominantly 6-methylmercaptopurine is produced instead of the desired 6-TGN, is also considered a reason for alternative thiopurine therapy. 14 Since part of the generated end metabolites of TG, being 6-TGN, is the same as during AZA and MP therapy, one could assume the same influence of TG on pregnancy outcomes.
Available data on the use of TG during pregnancy are scarce 15 and consists of only two patients with Crohn's disease [CD] with no adverse pregnancy outcomes. 16 Therefore, the aim of this study on female IBD patients was to describe the safety and teratogenicity of TG during pregnancy in a larger group of patients.
Materials and Methods

Study design
The VU University Medical Center [VUmc] IBD database was scrutinised for this retrospective study. The Initiative on Crohn and Colitis [ICC] and Nurses Initiative on Crohn and Colitis [NICC] network, being all university IBD centres in The Netherlands, were contacted as well, in search for additional cases, between 2003 and December 2014. Female IBD patients were included if they were treated with TG at some point during pregnancy. The two patients described by de Boer in 2005 were also included. 16 The primary goal of this study was to describe the number and aspect of birth defects, and in addition to portray the rate of miscarriage, preterm delivery [< 37 weeks], low birthweight, and neonatal morbidity. Secondary endpoints of this study were to describe complications during pregnancy, method of delivery, course after delivery, signs of myelosuppression or hepatotoxicity in the neonate, thiopurine metabolite measurements, and follow-up. Ethics approval was obtained from the medical ethics board of VU University Medical Center.
Demographic and IBD-related characteristics
At baseline, the following data on patient characteristics were collected: type of IBD [CD, ulcerative colitis [UC], or IBD unclassified], localisation of IBD, duration of IBD at initiation of TG treatment and conception, medication history, and co-medication. Data on duration between diagnosis, TG treatment, and conception were collected in whole years. Patients were classified according to the Montreal classification. 17 
Pregnancy outcome and neonatal characteristics
The following data were collected on obstetric history, pregnancy, and neonatal outcome: previous pregnancies and outcome, spontaneous abortions, course of pregnancy, flare of disease activity during pregnancy and treatment, fetal ultrasound abnormalities, mode of delivery, indications for operative delivery, gender, birthweight, gestational age at birth, congenital abnormalities, neonatal complications, and neonatal ward admission. Birthweight percentile categories were calculated according to gender and gestational age at birth. 18 
Laboratory tests
If measured, thiopurine metabolite 6-TGN concentrations in red blood cells [RBCs] were determined using the Dervieux method. 19 Existing literature generally utilises the Lennard method 20 for determination of thiopurine metabolites. To compare our data, 6-TGN concentrations were re-calculated by dividing the concentrations by a converting factor of 2.6.
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In blood, both cord blood and neonatal venepuncture, potential toxicity [bone marrow depression and hepatotoxicity] due to maternal thiopurine use was analysed. In newborns, leukopenia was defined as a leucocyte count below 5*10 9 /l, anaemia as a haemoglobin level below 10 mmol/l and thrombocytopenia as a platelet count below 150*10 9 /l 22 Table 1 .
Results
Maternal characteristics
Reasons 
Pregnancy characteristics
All 13 patients using TG during pregnancy, with a total of 19 pregnancies including one monochorionic twin pregnancy were included [ Table 2 ]. In line with good clinical practice, patients received a precounselling talk on the safety of TG treatment during pregnancy, using the scarce data. 15 
Pregnancy outcomes
Three pregnancies resulted in a spontaneous abortion [16%] in the first trimester during TG treatment. All three patients had an ongoing pregnancy in the years following the miscarriage during TG therapy. 
Neonatal complications
Admission to the neonatology unit was indicated in five newborns, of whom the characteristics are described in Table 3 . The monochorionic twins were both admitted to the neonatology unit because of infant respiratory distress syndrome [IRDS] grade 2, treated with continuous positive airway pressure [CPAP] , and postpartum transient hypotonia due to maternal labetalol use for pre-eclampsia. 
Laboratory testing
Five neonates were laboratory tested for myelosuppression in either cord blood or by neonatal thrombocytopenia. No anaemia, leukopenia, or thrombocytopenia was observed. No hepatotoxicity was found in the three neonates checked. No clinically relevant maternal liver test abnormalities were observed during pregnancy. Hypoglycaemia was detected in 60% of the five newborns tested.
Umbilical cord 6-TGN concentrations were measured in four newborns. In three, the 6-TGN concentration was below detectable level; in one newborn, the re-calculated concentration was 38 pmol/8*10 8 RBC. 16 
Comparison pregnancy cohort using conventional thiopurines
The population from a recent prospective cohort study in The Netherlands, on maternal conventional thiopurine therapy during pregnancy, 7 closely resembles our TG cohort as based on the patient and disease characteristics [ Table 1 ]. In addition, neonatal outcomes match with our rate of congenital abnormalities, birthweight ,and gestational age at birth [ Table 4 ].
Discussion
Our descriptive study demonstrates that TG treatment in pregnant IBD patients appears to be relatively safe: 19 pregnancies in 13 patients resulted in 17 neonates, including one with a mild congenital abnormality. Five newborns required [short-term] neonatal ward admission, including the twins after induced preterm labour. Low birthweight [< 2500 g] was only observed in these twins, and in none of the singletons.
Conventional thiopurine treatment during pregnancy in IBD patients is considered relatively safe. There is no association with an increase in the rate of congenital abnormalities or low birthweight when adjusted for disease activity, though it may increase the risk of preterm birth, 6 neonatal anaemia, and leukopenia. 7 Also, maternal thiopurine treatment during pregnancy does not seem to affect the long-term development or immune function of children up to 6 years of age. 10 As the metabolites of TG are partially the same as the metabolites of AZA and MP, a comparable impact of TG on pregnancy outcomes could be expected.
Therefore we compared our patient data and outcomes with a Dutch age-matched IBD cohort of 30 women taking conventional thiopurines during pregnancy. 7 As shown in Tables 1 and 4 , not only the patient group but also the pregnancy outcomes, i.e. birthweight and rate of congenital abnormalities, are highly similar.
In our study, the observed birthweight was comparable to the normal ranges within the data from the 10-year prospective perinatal registration in The Netherlands. 24 Low birthweight [LBW], specified as birthweight below 2500 g, occurred in our study only GA, gestational age; wk, weeks; LBW, low birthweight;
LGA, large for gestational age; SGA, small for gestational age. a Distal shaft hypospadias in patient #1/1 whose father also has a congenital hypospadias. A meta-analysis on the influence of IBD on pregnancy shows an increased rate of LBW in IBD patients compared with a non-IBD population. 3 In the general Dutch population, the rate of LBW is 6.9%. 24 In our cohort, no LBW was observed in the singleton pregnancies, whereas a French study on pregnancy outcome in IBD patients treated with conventional thiopurines shows a LBW rate of 15.8%. 8 Inflammatory bowel disease also influences the rate of prematurity [< 37 weeks of gestation] compared with controls. 3 In conventional maternal thiopurine treatment, rates up to 36.2% of preterm birth are reported, 8, 9 compared with 7.7% as documented by the perinatal registration in The Netherlands. 24 No preterm birth in singleton pregnancies was observed in our case series. Only the twin pregnancy resulted in an iatrogenic preterm birth.
One congenital abnormality was diagnosed, namely a distal shaft hypospadias in a neonate whose father also had congenital hypospadias. The prevalence of congenital hypospadias in The Netherlands is 19.8 per 10.000 births. 24 Studies on maternal thiopurine treatment in IBD report rates of 3.6-6.5% 7, 8, 9 of congenital abnormalities, whereas the rate of congenital abnormalities in the general population in The Netherlands is 2.7%. 26 However, next to an increased rate of low birthweight and prematurity, the meta-analysis on the influence of IBD on pregnancy also shows a 2.37-fold increased risk of congenital abnormalities compared with a non-IBD population. 3 Moreover, hypospadias shows familial clustering, 27 and environmental factors including maternal drug use during pregnancy are also contributing factors. 28 Therefore, we cannot determine whether the congenital hypospadias in this case is a consequence of IBD disease activity or maternal therapy, or has a familial cause.
Three pregnancies [16%] ended in a spontaneous abortion in the first trimester. Several maternal risk factors were present, including maternal age above 35 years, previous spontaneous abortions, comorbid PCOS and conception by IVF. 29 Since our cohort is relatively small, we believe no firm conclusions can be drawn from this rate.
In five newborns, a blood sample was drawn for analysis of potential toxicity [hepatotoxicity and myelosuppression] of maternal thiopurine therapy. No anaemia was present, although another study observed a rate of 60% [in 31 newborns] of anaemia after intrauterine exposure to conventional thiopurines. 7 We acknowledge several limitations in this retrospective study. Because of the design of the study, disease activity at conception and during pregnancy was not documented. Data on smoking and alcohol intake during pregnancy were not available in the outpatient gastroenterology medical reports. Dosage of medication was not recalculated to mg/kg since data on maternal weight were not retrospectively obtainable. We recognise the probable existence of missed and therefore unreported cases. Also, precise numbers on voluntarily childlessness using TG treatment are missing, though this finding is mentioned by several gastroenterologists contributing to this article. Despite the multicentre design, the sample size was relatively small; however, our study represents the largest case series so far in literature. In the majority of neonates no [long-] follow-up was performed.
Our study reveals a lower incidence of adverse pregnancy outcomes compared with the general Dutch population, though unfavourable effects of IBD disease activity itself were expected. 3 Low birthweight and preterm birth were not observed in the singleton pregnancies. This is a reassuring outcome, especially when compared with general data on IBD disease activity during pregnancy 3 and evidence on conventional maternal thiopurine therapy during pregnancy, 6 ,7 which show increased rates of both LBW and preterm birth. Only the twin pregnancy resulted in neonates with LBW after a preterm delivery, which is an average pregnancy outcome for twins. Also, the one [mild] congenital abnormality in this cohort has multifactorial potential causes. 3, 27, 28 In conclusion, this relatively small case series shows promising outcomes and supports safe use of TG in pregnant IBD patients. Although there is no evident proof of teratogenicity, consideration should be given to the indication and continuation of TG during pregnancy, and dedicated specialist teams are recommended for pregnancy management.
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